American College of Medical Genetics and Genomics Policy Statements


ACTIVE LIST


Title Copyright Publication

Alzheimer Disease

Consensus Statement on Use of Apolipoprotein E Testing for Alzheimer Disease

1995, AMA   1995 JAMA
274:1627-1629

Breast Cancer

xxx Statement on Population Screening for BRCA-1 Mutation in Ashkenazi Jewish Women    1996, ACMG   1996 ACMG
Newsletter 7:9

Carrier Screening
ACMG position statement on prenatal/ preconception expanded carrier screening 2013, ACMG 2013 Genet Med
15:6:482-483

Conflict of Interest
Conflict of Interest 2009, ACMG e-publicaton

Cystic Fibrosis

Laboratory Standards and Guidelines for Population Based Cystic Fibrosis Carrier Screening

2001, ACMG 2001 Genet Med 3:2:149-154

Down Syndrome

 

 

 

 

Statement on Nutritional Supplements & Piracetam for Children with Down Syndrome

1996, ACMG 1996 ACMG
Newsletter 6:12

Emergency Preparedness (Report)
Emergency preparedness for newborn screening and genetic services 2009, ACMG 2009 Genet Med
11:6:455-464

FISH
FISH2: FISH Technical and Clinical Assessment of: An ACMG/ASHG Position Statement. I: Technical Considerations
2000, ACMG 2000 Genet Med 
2:6:356-361

Folic Acid

Folic Acid and Neural Tube Defects

2010, ACMG 2010 Genet Med 
13:6:593-596

Genetic Discrimination
Points to Consider in Preventing Unfair Discrimination Based on Genetic Disease Risk: A Position Statement of the American College of Medical Genetics and Genomics
2001, ACMG
Reaffirmed 2005
2001 Genet Med 
3:6: 436-437

Genetic Testing
ACMG position statement on prenatal/ preconception expanded carrier screening 2013, ACMG 2013 Genet Med
15:6:482-483
Technical report: ethical and policy issues in genetic testing and screening of children

2013, ACMG/AAP 2013 Genet Med
15:3:234-245
Risk categorization for oversight of laboratory-developed tests for inherited conditions

2013, ACMG 2013 Genet Med
15:4:314-5
ACMG 2008 Policy Statement on Direct-to-Consumer Genetic Testing

2008, ACMG e-publication

Genetic Testing in Adoption (ACMG/ASHG)

2000, ASHG 2000 Am J Hum Genet 66:761-767

Genomic Sequencing
  ACMG Recommendations for reporting of incidental findings in clinical exome and genome sequencing 2013, ACMG 2013 Genet Med
15:7:565-578
  Incidental Findings in Clinical Genomics: A Clarification 2013, ACMG 2013 Genet Med
15:7:644-666
  Points to Consider for Informed Consent for Genome/Exome Sequencing 2013, ACMG Genet Med
15:9:748-749
  Points to Consider in the Clinical Application of Genomic Sequencing 2012, ACMG e-publication

Legal & Ethical Issues

ACMG Statement on Access to Reproductive Options After Prenatal Diagnosis



2013, ACMG 2013,
Genet Med 15:11:900

Duty to Re-Contact



1999, ACMG 1999 Genet Med
1:174-172
Guidelines for Expert Witness Testimony for the Specialty of Medical Genetics

2000, ACMG 2000 Genet Med
2:6:367-368
Position Statement on Gene Patents & Accessibility of Gene Testing 1999, ACMG
Reaffirmed 2005

1999 Genet Med
1:237

Statement on Storage & Use of Genetic Materials

1995, ASHG 1995 Am J Hum Genet 57: 1499-5000

Managed Care

Genetics and Managed Care

2001, ACMG
Reaffirmed 2005
2001 Genet Med
3:6:430-433

Microarrays
  American College of Medical Genetics and Genomics
recommendations for the design and performance
expectations for clinical genomic copy number
microarrays intended for use in the postnatal setting
for detection of constitutional abnormalities
2010, ACMG 2010 Genet Med
13:6:676-679

Newborn Screening
Position Statement on Importance of Residual Newborn Screening Dried Blood Spots 2009, ACMG

e-publication

Statement on Universal Newborn Hearing Screening

2000, ACMG
Reaffirmed 2005


2000 Genet Med
2:149-150

Tandem Mass Spectrometry in Newborn Screening

2000, ACMG

2000 Genet Med
2:267-269

Newborn Screening: Toward a Uniform Screening Panel and System

2006, ACMG 2006 Genet Med
8:5:Supplement

Pharmacogenetics

A Rapid ACCE1 Review of CYP2C9 and VKORC1 Allele Testing to Inform Warfarin Dosing in Adults at Elevated Risk for Thrombotic Events to Avoid Serious Bleeding

 

Click here to go to ACMG's comprehensive report on genetic testing and Warfarin dosing 

 

2008, AMCG 2008, Genet Med 10:89-98
Pharmacogenetic testing of CYP2C9 and VKORC1alleles for warfarin 2008, ACMG 2008, Genet Med 10:139-150

Prenatal Screening
Statement on noninvasive prenatal screening for fetal aneuploidy 2013, ACMG Genet Med 15:5:395-398

Scope of Practice
Medical Genetics Scope of Practice 2008, ACMG e-publication


 


RETIRED POLICY STATEMENTS

If you require copies of these retired documents, please contact ACMG at acmg@acmg.net


Title Copyright Date Retired

Carrier Testing for Canavan Disease

1998, ACMG

Retired 11/21/10
Direct-to-Consumer Genetic Testing 2004, ACMG

Retired 04/07/08

FISH1: Policy Statement on Prenatal Interphase 1993, ASHG

Retired 1/20/01
Folic Acid & Pregnancy 1994, ACMG Retired 10/26/04

Folic Acid: Statement on Fortification & Supplementation 1997, ACMG Retired 10/26/04


Policy Statement on Diagnostic and Carrier Testing for Fragile X Syndrome 1994,
Wiley-Liss
Reitred 11/03/05


Statement on Multiple Marker Screening in Pregnant Women: See Second Trimester Maternal Serum Screening for Fetal Open Neural Tube Defects and Aneuploidy

1996, ACMG Retired 9/22/04
Position Statement on Multiple Marker Screening in Women 35 and Older: See Second Trimester Maternal Serum Screening for Fetal Open Neural Tube Defects and Aneuploidy



1994, ACMG Retired 9/22/04